Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CDXS Codexis
6.510+0.190+3.01%
Close
02/07 16:00 ET
High
6.580
Open
6.270
Turnover
3.22M
Low
6.220
Pre Close
6.320
Volume
498.98K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Codexis (NASDAQ:CDXS) Rating Increased to Hold at StockNews.com
StockNews.com upgraded shares of Codexis (NASDAQ:CDXS – Get Rating) from a sell rating to a hold rating in a research report released on Tuesday. A number of other research firms also recently commen
Codexis, Inc. (NASDAQ:CDXS) Receives $19.83 Average PT From Analysts
Codexis, Inc. (NASDAQ:CDXS – Get Rating) has earned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. One analyst has ra
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Decreases By 7.0%
Codexis, Inc. (NASDAQ:CDXS – Get Rating) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 5,070,000 shares,
US Bancorp DE Has $89,000 Stake in Codexis, Inc. (NASDAQ:CDXS)
US Bancorp DE grew its position in Codexis, Inc. (NASDAQ:CDXS – Get Rating) by 21.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Insider Sell: Codexis
04:16 PM EST, 01/25/2023 (MT Newswires) -- John J Nicols, Director, on January 23, 2023, sold 75,499 shares in Codexis (CDXS) for $490,937. Following the Form 4 filing with the SEC, Nicols has control
Codexis Appoints Former Eiger BioPharmaceuticals CFO as Its Finance Chief
Codexis: Ryali Was Chief Fincl Officer of Eiger BioPharmaceuticals >CDXS
Codexis Names Sri Ryali as Chief Fincl Officer,Effective Immediately >CDXS
Codexis Announces Appointment of Sri Ryali as Chief Fincl Officer >CDXS
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately.
Company Overview
More
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
CEO： Dr. Stephen G. Dilly, M.D.
Market： NASDAQ
Listing Date： 04/22/2010
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet